immunotherapy approaches in lymphoma/media/images/swedish/cme... · immunotherapy in lymphoma -...
Post on 05-Jun-2020
1 Views
Preview:
TRANSCRIPT
Annual Oncology Symposium 5/20/2016
1
Immunotherapy Approaches in Lymphoma
John Kuruvilla MD FRCPC
Annual Oncology Symposium 5/20/2016
2
Research SupportLeukemia and Lymphoma Society US, Rasch FoundationRoche,
Employee N/A
Consultant Abbvie, BMS, Gilead, Janssen, Roche
Major Stockholder N/A
Speakers Bureau N/A
Honoraria Abbvie Amgen, BMS, Celgene, Gilead, Roche, Janssen, Lundbeck, Merck Seattle Genetics,
Scientific Advisory Board Lymphoma Canada (Chair)
I will likely discuss all sorts of off-label use of agents as well as investigational agents
Disclosures for John Kuruvilla MD
Annual Oncology Symposium 5/20/2016
3
The “old era” of immunotherapy
• A few examples in lymphoma of immunotherapy– Allogeneic stem cell transplantation– Interferon-a– Anti-idiotype vaccination
Annual Oncology Symposium 5/20/2016
4
Objectives – Immunotherapy Approaches in Lymphoma
• Assess the new era of immunotherapies• Review checkpoint inhibitors and adoptive
immunotherapies• Recognize how immunotherapies should be used
in lymphoma therapy.
• Create some controversy…
Annual Oncology Symposium 5/20/2016
5
First example of GVLY – Johns Hopkins Comparison of ASCT and ALLO
• N=118• ASCT 80 (purged)• ALLO 38• Pre-SCT status
predicts outcome• No OS difference• Reduced REL
suggestive of anti-tumour effect
ASCT
ALLO
Jones Blood 1991
Annual Oncology Symposium 5/20/2016
6
DLI and wIST in NHL
From Porter et al BBMT 2010
Annual Oncology Symposium 5/20/2016
7
IFN-2 in FL – Meta-Analysis Shows Benefit
• Meta-analysis performed of 10 randomized trials in newly diagnosed FL (1922 patients) – trial heterogeneity re:– Timing and dose of IFN– Type of chemotherapy given (anthracycline or not)
• Survival advantage demonstrated when:– In conjunction with relatively intensive chemo– Dose 5 million units– Cumulative dose 36 million units per month– IFN given with chemotherapy as opposed to as maintenance
Rohatiner et al. JCO Vol. 23 No. 10, 2005
Annual Oncology Symposium 5/20/2016
8
OS Advantage with maintenance IFN
Rohatiner et al. JCO Vol. 23 No. 10, 2005
Annual Oncology Symposium 5/20/2016
9
PFS Advantage with Immune Response (not vaccine) in FL
• Immune response assessed by development of humoral anti-Id antibody
Levy JCO 2014
Annual Oncology Symposium 5/20/2016
10
Mayo Clinic – Lymphocyte recovery post ASCT
• Multiple studies, but effectors or specific subsets not identified
NHL – OS post ASCT HL – OS post ASCT
Porrata Blood 2002; Porrata BJH 2002
Annual Oncology Symposium 5/20/2016
11
Summary of the old era• Therapies are non-specific• Allogeneic transplant may be the ultimate
adoptive immunotherapy– But it comes with a potential price
• Other therapies (IFN, vaccines etc.) have more modest benefit– Immune responsiveness may be an important
concept– Disease specific (FL different than DLBCL
which is different than HL)
Annual Oncology Symposium 5/20/2016
12
Immunotherapy – a problem of definition
• Think of all of the therapy you give as standard of care “chemotherapy
• How much of it may be immune active?RituximabBrentuximabLenalidomideAutologous transplantation
Annual Oncology Symposium 5/20/2016
13
So in the new era…
• Checkpoint inhibitors• A host of other antibody approaches• Cell-based therapies• Combination strategies• Signaling pathway inhibitors (PI3K, BTK
as examples)
• What’s ready for prime time?
Annual Oncology Symposium 5/20/2016
14
Role of the Immune Checkpoint• We need the immune system to
fight pathogens and help eliminate abnormal cells
• We also need to have controls on this system– Maintain tolerance and prevent
injury to self tissue• The immune checkpoint is the
series of inhibitory signals for this system– While designed for self control,
these signals can be exploited by cancer cells
Pardoll , 2012, Nat Rev Can, 5, 252‐265
Cancer Cell T‐cell
Annual Oncology Symposium 5/20/2016
15
Pardoll , 2012, Nat Rev Can, 5, 252‐265
Cancer Cell T‐cell
Immune Checkpoint Blockade
Annual Oncology Symposium 5/20/2016
16
• PathologyofcHL:raremalignantReed‐Sternbergcellswithinanextensiveinflammatory/immunecellinfiltrate.
• Geneticanalyses:frequent9p24.1amplificationwithupregulation ofPD‐1ligandsandJAK2.
• Hypothesis:cHL mayhaveageneticallydrivendependenceonPD‐1.
Relevance of the Immune Checkpoint in Classical HL
Juszczynski et al PNAS 2007; 104: 13134Green et al Blood 2010; 116: 3268; Chen et al. Clin Cancer Res 2013;
19:3462
Annual Oncology Symposium 5/20/2016
17
Readyforprimetime…
Annual Oncology Symposium 5/20/2016
18
Nivolumab in Patients (Pts) With Relapsed or Refractory Classical Hodgkin Lymphoma
(R/R cHL): Clinical Outcomes From Extended Follow‐up of a Phase 1 Study (CA209‐039)
Stephen M. Ansell, MD, PhD,1 Philippe Armand, MD, PhD,2 John Timmerman, MD,3Margaret A. Shipp, MD,2 M. Brigid Bradley Garelick, MD,4 Lili Zhu, MS,5
Alexander M. Lesokhin, MD6
1Mayo Clinic, Rochester, MN, USA; 2Dana‐Farber Cancer Institute, Boston, MA, USA; 3Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA; 4Bristol‐Myers Squibb, Wallingford, CT, USA; 5Bristol‐Myers Squibb, Princeton, NJ, USA;
6Memorial Sloan Kettering Cancer Center, New York, NY, USAPresented at ASH 2015
Annual Oncology Symposium 5/20/2016
19
Annual Oncology Symposium 5/20/2016
20
Compare and Contrast – 2 different PhaseII trials (at your peril)
Nivo PembroSchedule Q2Weekly Q2WeeklyToxicity 22% Grade 3 AE
No Grade 410% Grade 3 AENo Grade 4
ORR 87% 66%Time to Response 12W 12WPFS / DOR Median NR Median NR
Difficult to assess any differences at this pointNivolumab further ahead in development at this time (and has a published manuscript)
Annual Oncology Symposium 5/20/2016
21
PhilippeArmand1,JohnTimmerman2,AlexanderM.Lesokhin3,AhmadHalwani4,MichaelM.Millenson5,StephenJ.Schuster6,MartinGutierrez7,EmmaC.Scott8,
DeepikaCattry3,GordonJ.Freeman1,BjoernChapuy1,AzraH.Ligon9,ScottJ.Rodig9,LiliZhu10,JosephF.Grosso10,JasonSimon10,MargaretA.Shipp1,
AdamD.Cohen6,DanielLebovic11,MadhavDhodapkar12,DavidAvigan13,StephenM.Ansell14,IvanBorrello15
NivolumabinRelapsedorRefractoryLymphoidMalignanciesandClassicalHodgkinLymphoma:
UpdatedResultsofaPhase1Study
1Dana‐FarberCancerInstitute,Boston,MA;2JonssonComprehensiveCancerCenter,UniversityofCalifornia,LosAngeles,CA;3MemorialSloanKetteringCancerCenter,NewYork,NY;4UniversityofUtahHuntsmanCancerInstitute,SaltLakeCity,UT;5FoxChaseCancerCenter,Philadelphia,PA;6AbramsonCancerCenter,UniversityofPennsylvania,Philadelphia,PA;7JohnTheurerCancerCenter,HackensackUniversityMedicalCenter,Hackensack,NJ;8OregonHealthandScienceUniversity,Portland,Oregon;9Brighamand
Women’sHospital,Boston,MA;10Bristol‐MyersSquibb,Princeton,NJ;11UniversityofMichiganHematology,AnnArbor,MI;12YaleCancerCenter,NewHaven,CT;13BethIsraelDeaconessMedicalCenter,Boston,MA;14MayoClinic,Rochester,MN;15JohnsHopkinsUniversity
SchoolofMedicineandtheSidneyKimmelComprehensiveCancerCenter,Baltimore,MDEHA 20 TH CONGRES S
JUNE 2015V I ENNA , AUSTR IA
Annual Oncology Symposium 5/20/2016
22
Annual Oncology Symposium 5/20/2016
23
Summary of anti-PD1 Ab Activity in Lymphoma
Agent Histology N ORR (%)
Nivo HL 23 87
Pembro HL 31 66
Nivo TCL 23 17
Nivo FL 10 40
Nivo DLBCL 11 36
Nivo PMBL 2 0 (2SD)
Pembro PMBL 10 40
Ansell ASH 2015, Armand ASH 2015, Armand EHA 2015, Zinzani ASH 2015
Annual Oncology Symposium 5/20/2016
24
Immunotherapy in Lymphoma -Summary
• Long history of usage of immune-based therapy in lymphoma– Frequently employed non-specifically
• Checkpoint inhibition is a specific targeted strategy that appears safe with promising activity– Development in NHL is less clear
• Biologic insights are needed– HL is an excellent paradigm
Annual Oncology Symposium 5/20/2016
25
Immunotherapy in Lymphoma –Conclusions
• PD1 inhibition is a new paradigm in the treatment of REL/REF HL– Appears to be new standard post brentuximab
failure• PD1 inhibition requires further development in
NHL– Biology and biomarkers needed
• Multiple new immunotherapies in development
top related